Perspective The Future of SARS-CoV-2 Vaccination — Lessons from Influenza List of authors. Arnold S. Monto, M.D. November 6, 2021 DOI: 10.1056/NEJMp2113403 Article Figures/Media Metrics 5 References Comment Comments open through November 17, 2021 Article After a period of falling Covid-19 illness rates, the recent spread of the delta variant of SARS-CoV-2 was a major disappointment and necessitated a reexamination of some previous assumptions. This reconsideration may, at least in part, be a correction to overly optimistic views of what highly effective SARS-CoV-2 vaccines could accomplish. Some observers had hoped the vaccines could eliminate transmission of the virus, the ultimate goal of reaching herd immunity. 1 A more likely picture of our future with this virus comes into focus if we examine the well-known infection patterns of another respiratory virus, influenza, both in and outside pandemics. That experience can help us reset expectations and modify goal...
Entradas
- Obtener enlace
- X
- Correo electrónico
- Otras aplicaciones
ORIGINAL ARTICLE Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab List of authors. Anil Gupta, M.D., Yaneicy Gonzalez-Rojas, M.D., Erick Juarez, M.D., Manuel Crespo Casal, M.D., et al., for the COMET-ICE Investigators * October 27, 2021 DOI: 10.1056/NEJMoa2107934 Article Figures/Media Metrics 27 References Abstract BACKGROUND Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a...